- Home
- HBB vs CRBP Comparison
HBB vs CRBP Comparison
Compare HBB & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- CRBP
- Stock Information
- Founded
- HBB 1904
- CRBP 2009
- Country
- HBB United States
- CRBP United States
- Employees
- HBB N/A
- CRBP N/A
- Industry
- HBB Home Furnishings
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- HBB Consumer Discretionary
- CRBP Health Care
- Exchange
- HBB Nasdaq
- CRBP Nasdaq
- Market Cap
- HBB 196.2M
- CRBP 233.5M
- IPO Year
- HBB 2017
- CRBP N/A
- Fundamental
- Price
- HBB $14.55
- CRBP $17.12
- Analyst Decision
- HBB
- CRBP Strong Buy
- Analyst Count
- HBB 0
- CRBP 9
- Target Price
- HBB N/A
- CRBP $49.00
- AVG Volume (30 Days)
- HBB 25.2K
- CRBP 394.1K
- Earning Date
- HBB 10-29-2025
- CRBP 11-07-2025
- Dividend Yield
- HBB 3.30%
- CRBP N/A
- EPS Growth
- HBB N/A
- CRBP N/A
- EPS
- HBB 2.35
- CRBP N/A
- Revenue
- HBB $631,318,000.00
- CRBP N/A
- Revenue This Year
- HBB N/A
- CRBP N/A
- Revenue Next Year
- HBB N/A
- CRBP $220.00
- P/E Ratio
- HBB $6.20
- CRBP N/A
- Revenue Growth
- HBB N/A
- CRBP N/A
- 52 Week Low
- HBB $12.72
- CRBP $4.64
- 52 Week High
- HBB $31.12
- CRBP $20.77
- Technical
- Relative Strength Index (RSI)
- HBB 47.13
- CRBP 60.08
- Support Level
- HBB $14.48
- CRBP $16.40
- Resistance Level
- HBB $15.20
- CRBP $20.56
- Average True Range (ATR)
- HBB 0.57
- CRBP 1.81
- MACD
- HBB -0.02
- CRBP -0.21
- Stochastic Oscillator
- HBB 35.05
- CRBP 50.86
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.